Jefferies Financial Group Comments on Five Prime Therapeutics Inc’s Q1 2019 Earnings (FPRX)

Five Prime Therapeutics Inc (NASDAQ:FPRX) – Equities researchers at Jefferies Financial Group issued their Q1 2019 earnings per share (EPS) estimates for shares of Five Prime Therapeutics in a research note issued on Wednesday, November 7th. Jefferies Financial Group analyst E. Yang forecasts that the biotechnology company will post earnings per share of ($1.29) for the quarter. Jefferies Financial Group also issued estimates for Five Prime Therapeutics’ Q2 2019 earnings at ($1.31) EPS, Q3 2019 earnings at ($1.34) EPS and Q4 2019 earnings at ($1.35) EPS.

A number of other brokerages also recently issued reports on FPRX. Citigroup lowered their price target on Five Prime Therapeutics from $60.00 to $44.00 and set a “buy” rating on the stock in a research report on Monday, August 20th. Wells Fargo & Co lowered their price target on Five Prime Therapeutics from $58.00 to $35.00 and set an “outperform” rating on the stock in a research report on Thursday, August 9th. BidaskClub downgraded Five Prime Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, August 15th. Wedbush increased their price target on Five Prime Therapeutics from $17.00 to $19.00 and gave the stock a “hold” rating in a research report on Friday, August 10th. Finally, ValuEngine downgraded Five Prime Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, July 28th. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating and five have given a buy rating to the company’s stock. Five Prime Therapeutics currently has an average rating of “Hold” and an average price target of $29.67.

Shares of FPRX stock opened at $11.49 on Thursday. Five Prime Therapeutics has a 12-month low of $10.35 and a 12-month high of $30.25.

Five Prime Therapeutics (NASDAQ:FPRX) last issued its quarterly earnings results on Tuesday, November 6th. The biotechnology company reported ($1.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.15) by ($0.22). The business had revenue of $5.77 million for the quarter, compared to analysts’ expectations of $7.45 million. Five Prime Therapeutics had a negative return on equity of 40.73% and a negative net margin of 221.67%.

Several institutional investors have recently made changes to their positions in FPRX. Northern Trust Corp raised its holdings in shares of Five Prime Therapeutics by 14.5% during the first quarter. Northern Trust Corp now owns 370,040 shares of the biotechnology company’s stock valued at $6,357,000 after acquiring an additional 46,742 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of Five Prime Therapeutics by 6.9% during the first quarter. Dimensional Fund Advisors LP now owns 1,041,750 shares of the biotechnology company’s stock valued at $17,897,000 after acquiring an additional 67,474 shares during the last quarter. UBS Group AG raised its holdings in shares of Five Prime Therapeutics by 773.8% during the first quarter. UBS Group AG now owns 98,653 shares of the biotechnology company’s stock valued at $1,695,000 after acquiring an additional 87,363 shares during the last quarter. The Manufacturers Life Insurance Company raised its holdings in shares of Five Prime Therapeutics by 17.8% during the first quarter. The Manufacturers Life Insurance Company now owns 25,032 shares of the biotechnology company’s stock valued at $430,000 after acquiring an additional 3,782 shares during the last quarter. Finally, California State Teachers Retirement System raised its holdings in shares of Five Prime Therapeutics by 16.9% during the first quarter. California State Teachers Retirement System now owns 50,093 shares of the biotechnology company’s stock valued at $861,000 after acquiring an additional 7,238 shares during the last quarter. 86.40% of the stock is owned by institutional investors and hedge funds.

Five Prime Therapeutics Company Profile

Five Prime Therapeutics, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of immuno-oncology protein therapeutics. The company's product candidates include Cabiralizumab, an antibody that inhibits colony stimulating factor-1 receptor that is in Phase Ia/Ib clinical trials for the treatment of various cancers in combination with nivolumab; and is in Phase I/II clinical trials for the treatment of pigmented villonodular synovitis tumor.

Featured Article: What does cost of debt say about a company’s financial health?

Earnings History and Estimates for Five Prime Therapeutics (NASDAQ:FPRX)

Receive News & Ratings for Five Prime Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply